blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2363022

EP2363022 - Use of oxygen antagonists for the therapeutic treatment of mammals [Right-click to bookmark this link]
StatusThe application has been refused
Status updated on  23.03.2018
Database last updated on 14.09.2024
Most recent event   Tooltip23.03.2018Refusal of applicationpublished on 25.04.2018  [2018/17]
Applicant(s)For all designated states
Fred Hutchinson Cancer Research Center
1100 Fairview Avenue North,C2M 027, P.O.Box 19024
Seattle, WA 98109-1024 / US
[2011/36]
Inventor(s)01 / Roth, Mark, B.
508 North Bowdoin Place
Seattle, WA 98103 / US
02 / Blackstone, Eric
1412 Summit Avenue No. 403
Seattle, WA 98122 / US
 [2011/36]
Representative(s)Griffin, Philippa Jane, et al
Mathys & Squire The Shard
32 London Bridge Street
London SE1 9SG / GB
[N/P]
Former [2011/36]Griffin, Philippa Jane, et al
Mathys & Squire LLP 120 Holborn London
EC1N 2SQ / GB
Application number, filing date11157706.022.10.2004
[2011/36]
Priority number, dateUS20030513458P22.10.2003         Original published format: US 513458 P
US20040548150P26.02.2004         Original published format: US 548150 P
US20040577942P08.06.2004         Original published format: US 577942 P
[2011/36]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP2363022
Date:07.09.2011
Language:EN
[2011/36]
Type: A3 Search report 
No.:EP2363022
Date:21.12.2011
Language:EN
[2011/51]
Search report(s)(Supplementary) European search report - dispatched on:EP23.11.2011
ClassificationIPC:A01N1/02
[2011/36]
CPC:
C12N5/00 (EP,US); A01N1/02 (EP,US); A01N1/0221 (EP,US);
C12N2500/02 (EP,US)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2011/36]
TitleGerman:Verwendung von Sauerstoff-Antagonisten für die therapeutische Behandlung von Saugetieren[2011/36]
English:Use of oxygen antagonists for the therapeutic treatment of mammals[2011/36]
French:Utilisation d'antagonistes d'oxygène pour le traitement thérapeutique de mammifères[2011/36]
Examination procedure07.04.2011Examination requested  [2011/36]
20.06.2012Amendment by applicant (claims and/or description)
29.01.2013Despatch of a communication from the examining division (Time limit: M06)
30.07.2013Reply to a communication from the examining division
12.06.2015Cancellation of oral proceeding that was planned for 16.06.2015
16.06.2015Date of oral proceedings (cancelled)
07.07.2015Despatch of communication that the application is refused, reason: substantive examination [2018/17]
03.02.2016Application refused, date of legal effect [2018/17]
Appeal following examination07.09.2015Appeal received No.  T0206/16
03.02.2016Result of appeal procedure: appeal of the applicant withdrawn
Parent application(s)   TooltipEP04796043.0  / EP1684579
Divisional application(s)EP15165996.8  / EP2949212
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20040796043) is  02.03.2009
Fees paidRenewal fee
20.04.2011Renewal fee patent year 03
20.04.2011Renewal fee patent year 04
20.04.2011Renewal fee patent year 05
20.04.2011Renewal fee patent year 06
20.04.2011Renewal fee patent year 07
11.10.2011Renewal fee patent year 08
26.10.2012Renewal fee patent year 09
28.10.2013Renewal fee patent year 10
27.10.2014Renewal fee patent year 11
27.10.2015Renewal fee patent year 12
Penalty fee
Additional fee for renewal fee
31.10.201613   M06   Not yet paid
31.10.201714   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO9813058  (UNIV COLUMBIA [US], et al) [X] 1,5,10-15 * abstract *;
 [X]FR2816212  (AIR LIQUIDE SANTE INT [FR]) [X] 1,5,10-15 * abstract *;
 [A]WO03072024  (BETH ISRAEL HOSPITAL [US], et al) [A] 1,5,10-15 * abstract * * page 2, line 2 - line 4 * * page 4, line 13 - line 18 *;
 [X]RU2177299  ;
 [X]RU2177774
 [A]  - SATO K ET AL, "Carbon monoxide generated by heme oxygenase-1 suppresses the rejection of mouse-to-rat cardiac transplants", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20010101), vol. 166, ISSN 0022-1767, pages 4185 - 4194, XP002314148 [A] 1,5,10-15 * abstract *
 [X]  - BROUARD S ET AL, "Carbon monoxide generated by heme oxygenase 1 suppresses endothelial cell apoptosis", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US, (20001002), vol. 192, no. 7, doi:10.1084/JEM.192.7.1015, ISSN 0022-1007, pages 1015 - 1025, XP002367559 [X] 1,5,10-15 * abstract * * page 1022, column 1, paragraph 1 *

DOI:   http://dx.doi.org/10.1084/jem.192.7.1015
 [X]  - DATABASE WPI, 0, Derwent World Patents Index, vol. 2002, no. 17, Database accession no. 2002-129020, XP002652216 & RU2177299 C2 20011227 (BLACK SEA HEALTH RESORT TREATMENT) [X] 1,5,10-15 * abstract *
 [X]  - DATABASE WPI, 0, Derwent World Patents Index, vol. 2002, no. 22, Database accession no. 2002-170428, XP002652217 & RU2177774 C2 20020110 (BLACK SEA HEALTH RESORT TREATMENT) [X] 1,5,10-15 * abstract *
by applicantUS6602277
 US5801005
 US5739169
 US5830880
 US5846945
 US6524785
 US6492103
 US6365338
 US6054261
 US5719174
 US5693462
 US5599659
 US5552267
 US5405742
 US5370989
 US5066578
 US4938961
 US4798824
 US5736397
 US6490880
 US6046046
 US5476763
 US5285657
 US3995444
 US3881990
 US3777507
 US5912019
 US5952168
 US5217860
 US4559258
 US6187529
 US5752929
 US5395314
 US5699793
 US6552083
 US4292817
 US4473637
 US4745759
 US5434045
 US4723974
 US6100082
 US5326706
 US5157930
 US4951482
 US4502295
 US4186565
 US5543158
 US5641515
 US5399363
 US5466468
 US4034753
 US4266573
 US4442856
 US5568910
 US5645081
 US5636643
 US4447415
 US4828976
 US5231025
 US5470738
 US5569579
 US5580781
 US6013256
 US6057148
 US6790603
    - LEDINGHAM ET AL., J. THORAC. CARDIOBASC. SURG., (1987), vol. 93, pages 240 - 246
    - LEDINGHAM ET AL., CIRCULATION, (1990), vol. 82, pages IV351 - 8
    - MENASCHE, J., EUR. J. CARDIO. THORAX. SURG., (1994), vol. 8, pages 207 - 213
    - BERNARD ET AL., J. THORAC. CARDIOVASC. SURG., (1985), vol. 90, pages 235 - 242
    - KURODA ET AL., TRANSPLANTATION, (1988), vol. 46, no. 3, pages 457 - 460
    - Remington's Pharmaceutical Sciences, pages 1035 - 1038,157
    - ALAM, ANTIOXID REDOX SIGNAL, (2002), vol. 4, no. 4, pages 559 - 62
    - AMERSI, HEPATOLOGY, (2002), vol. 35, no. 4, pages 815 - 823
    - AUSTIN-WARD; VILLASECA, REVISTA MEDICA DE CHILE, (1998), vol. 126, no. 7, pages 838 - 845
    - BEHRINGER ET AL., CRIT. CARE MED., (2003), vol. 31, no. 5, pages 1523 - 1531
    - BELLAMY ET AL., "24", CRIT. CARE MED., (1996), no. 2, pages 24 - 47
    - BOYCE; HAM, J. INVEST. DERMATOL., (1983), vol. 81, pages 335 - 405
    - BOYCE; HAM, J. TISSUE CULTURE METHODS, (1985), vol. 9, pages 83 - 93
    - BRIESE, NEUROSCI. BIOBEHAV. REV., (1998), vol. 22, no. 3, pages 427 - 436
    - BRIZEL, SEMINARS RADIATION ONCOL., (1998), vol. 8, no. 4, pages 17 - 20
    - BROUARD ET AL., J BIOL. CHEM., (2002), vol. 277, no. 20, pages 17950 - 17961
    - BUKOWSKI ET AL., CLINICAL CANCER RES., (1998), vol. 4, no. 10, pages 2337 - 2347
    - CHRISTODOULIDES ET AL., MICROBIOLOGY, (1998), vol. 144, pages 3027 - 3037
    - "90 day vapor inhalation toxicity study of hydrogen sulfide", Toxigenics, CHEMICAL INDUSTRY INSTITUTE OF TOXICOLOGY, (1983), pages 420 - 0710
    - CURRAN, SEMINARS RADIATION ONCOL., (1998), vol. 8, no. 4, pages 2 - 4
    - DAVIDSON ET AL., J. IMMUNOTHER., (1998), vol. 21, no. 5, pages 389 - 398
    - DILLMAN, CANCER BIOTHER. RADIOPHARM., (1999), vol. 14, no. 1, pages 5 - 10
    - DORMAN ET AL., NEUROTOXICOL. TERATOL., (2000), vol. 22, no. 1, pages 71 - 84
    - DULAK ET AL., ANTIOXID. REDOX SIGNAL, (2002), vol. 4, no. 2, pages 229 - 240
    - ETO ET AL., BIOCHEM. BIPHYS. RES. COMMUN., (2002), vol. 293, pages 1483 - 1488
    - GANTHER, CARCINOGENESIS, (1999), vol. 20, no. 9, pages 1657 - 66
    - GILBERT ET AL., LANCET, (2000), vol. 355, pages 375 - 376
    - GORMAN ET AL., TOXICOLOGY, (2003), vol. 187, no. 1, pages 25 - 38
    - GUILLEMIN ET AL., CELL, (1997), vol. 89, no. 1, pages 9 - 12
    - HAASE ET AL., ANNALS OF SURGERY, (2004), vol. 240, no. 2, pages 364 - 373
    - HANIBUCHI ET AL., INTL. J. CANCER, (1998), vol. 78, no. 4, pages 480 - 45
    - HELLSTRAND ET AL., ACTA ONCOLOGICA, (1998), vol. 37, no. 4, pages 347 - 353
    - HIGUCHI; FUKAMACHI, FOLIA PHARMACOLOGICA JAPONICA, (1977), vol. 73, no. 3, pages 307 - 319
    - HOCHACHKA ET AL., COMP. BIOCHEM. PHYSIOL. B BIOCHEM. MOL. BIOL., (2001), vol. 130, no. 4, pages 435 - 459
    - HOCHACHKA ET AL., PROC. NATL. ACAD. SCI. USA, (1996), vol. 93, no. 18, pages 9493 - 94938
    - HUI; HASHIMOTO, INFECTION IMMUN., (1998), vol. 66, no. 11, pages 5329 - 5336
    - HYSPLER ET AL., J. CHROMATOGRAPHY, (2002), vol. 770, pages 255 - 259
    - JIANG ET AL., AM. J. PHYSIOL. CELL PHYSIOL., (2001), vol. 280, pages 1140 - 1150
    - JU ET AL., J. NEUROPATHOL. EXP. NEUROL., (2000), vol. 59, no. 3, pages 241 - 50
    - KHAN ET AL., TOXICOL. APPLIED PHARMACOL., (1990), vol. 103, pages 482 - 490
    - KILBURN; WARSHAW, TOXICOLOGY INDUST. HEALTH, (1995), vol. 11, no. 2, pages 185 - 197
    - KILBURN, ENVIRON. HEALTH, (1999), vol. 54, no. 3, page 150
    - KILBURN, ENVIRON. RES., (1999), vol. 81, no. 2, pages 92 - 99
    - KUBULUS ET AL., "The mechanism of the delay phenomenon: tissue protection is mediated by heme oxygenase-1", INSTITUTE FOR CLINICAL EXPERIMENTAL SURGERY, (2004), pages 1 - 21
    - LEDINGHAM ET AL., CIRCULATION, (1990), vol. 82, no. 2, pages V351 - 358
    - LUNDGREN-ERIKSSON ET AL., ANTICANCER RES., (200109), vol. 21, no. 5, pages 3269 - 74
    - MENASCHE ET AL., EUR. J. CARDIO. THORAX. SURG., (1994), vol. 8, pages 207 - 213
    - NYSTUL ET AL., SCIENCE, (2003), vol. 302, no. 5647, pages 1038 - 1041
    - OTTERBEIN ET AL., AM. J. PHYSIOL. LUNG CELL MOL. PHYSIOL., (2000), vol. 279, no. 6, pages L1029 - L1037
    - OTTERBEIN ET AL., TRENDS IMMUNOL., (2003), vol. 24, no. 8, pages 449 - 455
    - PADILLA ET AL., MOLEC. BIOLOGY OFTHE CELL, (2002), vol. 13, pages 1473 - 1483
    - PADILLA ET AL., PROC. NATL. ACAD. SCI. USA, (2001), vol. 98, no. 13, pages 7331 - 7335
    - PARTLO ET AL., NEUROTOXICOLOGY, (2001), vol. 22, no. 2, pages 177 - 189
    - PETERSEN, BIOCHEMICA ET BIOPHYSICA ACTA, (1977), vol. 460, pages 299 - 307
    - PIETRAS ET AL., ONCOGENE, (1998), vol. 17, no. 17, pages 2235 - 2249
    - QIN ET AL., PROC. NATL. ACAD. SCI. USA, (1998), vol. 95, no. 24, pages 14411 - 14416
    - Remington's Pharmaceutical Sciences, MACK PUBLISHING COMPANY, (1980), pages 1035 - 1038,157
    - ROGER ET AL., GENOME, (1997), vol. 8, pages 711 - 713
    - RYTER; OTTERBEIN, BIOESSAYS, (2004), vol. 26, pages 270 - 280
    - SEMENZA, CELL, (1999), vol. 98, no. 3, pages 281 - 284
    - SEMENZA, TRENDS MOL. MED., (2001), vol. 7, no. 8, pages 345 - 350
    - STRUVE ET AL., NEUROTOXICOLOGY, (2001), vol. 22, no. 3, pages 375 - 385
    - TEODORO; OFARRELL, EMBO J., (2003), vol. 22, no. 3, pages 580 - 587
    - TISHERMAN, CRIT. CARE MED., (2004), vol. 32, no. 2, pages S46 - S50
    - VAN VOORHIES ET AL., J. EXP. BIOL., (2000), vol. 203, pages 2467 - 2478
    - WANG, FASEB J., (2002), vol. 16, no. 13, pages 1792 - 1798
    - ZHANG ET AL., J. APPL. PHYSIOL., (2004), vol. 96, no. 1, pages 392 - 397
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.